Sunday, October 2, 2022

561.316.3330

Biotechnology News Magazine

Antiverse Raises £1.4 Million ($2 million USD)

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

March 15, 2021

Antiverse is a biotechnology company developing a computational antibody drug discovery platform, has raised seed funding totalling £1.4 million ($2 million USD), comprising new investment and match funding from the UKI2S Innovate Accelerator.

The funding will be used to further develop Antiverse’s AI antibody drug discovery platform, which rapidly and accurately predicts antibody-antigen binding to identify antibody drug candidates.

Investors in the seed funding round include Development Bank of Wales, Angel Co-Investment Fund, Tensor Ventures, Wren Capital, Ed Parkinson, Cambridge Angels, and SyndicateRoom. A portion of the capital raised will be used to build a laboratory in Cardiff, Wales, and expand the technical team through the recruitment of specialist machine learning engineers, laboratory scientists, and structural biologists.

Antiverse is combining machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to provide diverse antibody candidates for any given target. The technology will enable the development of drugs for “difficult” targets associated with cancer, heart, and lung diseases.

Murat Tunaboylu, Chief Executive Officer of Antiverse, said: “Our investors recognize the potential of our AI-powered antibody drug discovery platform to provide a breakthrough in the industry. With our technology, it will be possible to develop drugs for difficult targets and ultimately reduce drug discovery timescales from years to weeks. In addition to platform development, the funding will enable us to invest in facilities and recruitment; we are grateful to our investors and Innovate UK for their continued support.”

Ed Parkinson, the lead investor for the syndicate of Angel Investors, commented: “Antiverse has an ambitious team of AI experts and scientists with a vision to transform drug discovery. This is a great example of a world-class business taking off in Wales with the support of the Development Bank of Wales.”

Martin Drdul, founder & general partner of Tensor Ventures, said:”We are very excited and confident investing into Antiverse. The company has great ambitions and shows huge potential in the intersection of biology and AI.”

Rafael Joseph, Development Bank of Wales, commented: “Together with our Wales Angel Co-Investment Fund, the Development Bank is helping more Welsh businesses to grow with equity funding; creating impact for the benefit of the Welsh economy. Our angel syndicates and networks are active across Wales and we are delighted to be supporting Antiverse on its journey with our seed investment. The Company really is at the cutting edge of using AI to augment and speed up the drug discovery process. Their work is transformational and it’s very exciting that it is happening here in Wales.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine